A major clinical problem in the use of cisplatin to treat cancers is tumor resistance. DNA polymerase h (Pol-h) is a crucial polymerase that allows cancer cells to cope with the cisplatin-DNA adducts that are formed during chemotherapy. We present here a structure of human Pol-h inserting deoxycytidine triphosphate (dCTP) opposite a cisplatin intrastrand cross-link (PtGpG). We show that the specificity of human Pol-h for PtGpG derives from an active site that is open to permit Watson-Crick geometry of the nascent PtGpG-dCTP base pair and to accommodate the lesion without steric hindrance. This specificity is augmented by the residues Gln38 and Ser62, which interact with PtGpG, and Arg61, which interacts with the incoming dCTP. Collectively, the structure provides a basis for understanding how Pol-h in human cells can tolerate the DNA damage caused by cisplatin chemotherapy and offers a framework for the design of inhibitors in cancer therapy.
a r t i c l e s Cisplatin and its related analogs are the mainstays of modern cancer chemotherapy. Approved by the US Food and Drug Administration in 1978, cisplatin has been used to treat a variety of cancers, ranging from ovarian and cervical to non-small-cell lung cancer, among others 1, 2 . The cytotoxicity of cisplatin toward cancer cells derives from its impeding of processes such as DNA replication and transcription, leading to cellular apoptosis. In particular, the platinum atom binds covalently to the N7 position of adjacent guanines to form 1, 2 intrastrand cross-links (PtGpGs) (Fig. 1a) , which cannot be bypassed by the classic replicative DNA polymerases (Pol-α, Pol-δ and Pol-ε), and DNA synthesis comes to a halt. A major drawback in the use of cisplatin, however, is acquired or intrinsic tumor resistance during the course of therapy 3 . This resistance can be mediated by a number of cellular processes, including translesion DNA synthesis (TLS) 1, 4 .
Humans have four TLS polymerases, Pol-η, Pol-κ, Pol- and Rev1, each of which has a unique DNA-damage-bypass and fidelity profile 5 . Pol-η is unique among these polymerases in its ability to replicate through UV-induced intrastrand cross-linked cis-syn thymine-thymine dimers 6 . Inactivation of Pol-η in humans causes the variant form of xeroderma pigmentosum (XPV) 6, 7 , a genetic disorder characterized by a greatly enhanced predisposition to sun-induced skin cancers. The crystal structures of yeast Saccharomyces cerevisiae and human Pol-η with undamaged and UV-damaged DNAs show that the Pol-η active site cleft is more open or spacious than it is in other DNA polymerases 8, 9 , allowing a cis-syn thymine-thymine dimer to be accommodated within it.
In addition to its role in suppressing skin cancers, Pol-η has also emerged as the main TLS polymerase that allows cancer cells to cope with the cisplatin-DNA adducts that are formed during cancer chemotherapy. Pol-η bypasses PtGpG cross-links more efficiently than other polymerases [10] [11] [12] , and the absence of functional Pol-η in XPV cells correlates with the sensitivity of these cells to cisplatin 10, 11, 13 . In addition, the amount of endogenous Pol-η has been found to be a reliable marker of cisplatin efficacy in non-smallcell lung cancer cell lines 14 . As such, Pol-η is a target for cancer therapy, whereas inhibiting Pol-η may increase the efficacy of traditional cisplatin chemotherapy.
How human Pol-η bypasses cisplatin-DNA adducts during TLS is unclear. A medium-resolution crystal structure of yeast Pol-η bound to a cisplatin-DNA adduct has been reported, but a number of its structural features are unclear 9, 15 . We report here a high-resolution crystal structure of the catalytic domain of human Pol-η inserting dCTP opposite the 3′ guanine of a PtGpG cross-link. This structure provides a molecular basis for understanding how Pol-η in human cells can tolerate the DNA damage caused by cisplatin chemotherapy and offers a framework for the design of inhibitors in future cancer therapy.
RESULTS

Structure determination
We cocrystallized the catalytic core of human Pol-η (residues 1-432) with a primer-template (9 nt and 13 nt, respectively) presenting the 3′ guanine of a PtGpG adduct as a templating base and with dCTP as the incoming nucleotide. We introduced the cisplatin modification between two adjacent guanines in the template strand (5′-CTTGGTCTCCTCC-3′) using a previously described method 16 . Several rounds of microseeding were required to produce cocrystals of good quality, which diffracted to 2.32-Å resolution with synchrotron a r t i c l e s radiation at the L III absorption edge of platinum (λ = 1.0722 Å). We solved the structure by the molecular replacement method using the human Pol-η ternary structure with undamaged DNA as the search model (PDB 3MR2) 8 . The refined model includes residues 2-432 of the protein (residues 156, 157 and 410-412 could not be modeled because of a lack of electron density), nucleotides 2-9 of the primer strand, nucleotides 4-13 of the template strand, 1 dCTP molecule, 1 magnesium ion and 116 water molecules ( Table 1) . The resulting structure has good stereochemistry ( Fig. 1) , with 97.9% of the residues located in the most favored regions of the Ramachandran plot based on analysis using MolProbity 17 .
As with undamaged DNA 8 , human Pol-η embraces the PtGpG primer-template with its palm, fingers and thumb domains, as well as its polymerase-associated domain (PAD; also known as the little finger domain) that is unique to the Y-family polymerases (Fig. 1b,c) . The palm carries the active site residues, Asp13, Asp115 and Glu116, which catalyze the nucleotidyl transfer reaction at dNTP binding. The fingers domain is located above the templating PtGpG-dCTP base pair, whereas the thumb and the PAD straddle the duplex portion of the primer-template ( Fig. 1b,c) . The thumb domain skims the minor groove surface of the DNA, making contacts with the sugarphosphate backbone of the primer strand. The PAD docks in the major groove and interacts extensively with the template and primer strands ( Supplementary Fig. 1 ). In particular, the main chain amides on the 'outer' β-strands of the PAD β-sheet make a series of hydrogen bonds with the sugar-phosphate backbones of the template and primer strands. The DNA remains essentially in the B form, except at the site of the PtGpG adduct ( Fig. 1) . The average DNA helical twist and rise values are 32.7° and 3.3 Å, respectively.
Cisplatin resides in an open active cleft
Even though PtGpG is a larger and a more distorted DNA cross-link than a UV-induced cis-syn thymine-thymine dimer ( Fig. 1) , human Pol-η accommodates this bulky lesion remarkably well, with only a small (~1 Å) outward movement of the fingers domain, compared to human Pol-η structures with undamaged and UV-damaged DNAs 8 ( Fig. 2a,b) . Therefore, as in the case of UV-damaged DNA, the crucial feature of human Pol-η that allows it to accommodate a cisplatin intrastrand cross-link is an active site cleft that is more open than it is in other DNA polymerases, including other TLS polymerases. Fig. 2c-e ). Human Pol-κ would thus require a larger conformational rearrangement than human Pol-η to accommodate a PtGpG adduct. The steric clashes are even more severe if the two polymerases are superimposed based on their respective template DNA strands ( Supplementary Fig. 2) .
The human Pol-η active site cleft contains residues that make specific interactions with the PtGpG adduct ( Fig. 3a) . The 3′ guanine of PtGpG is stabilized by a hydrogen bond between its N3 atom and the N-ε2 amino group of Gln38, analogous to the hydrogen bond between the O2 carbonyl of the 3′ thymine of the thymine-thymine dimer and N-ε2 of Gln38 in the structure of human Pol-η with UV-damaged DNA 8 (Fig. 3) . Accordingly, a Q38A mutation confers a ~70% reduction in the catalytic efficiency of human Pol-η for the incorporation of dCTP opposite the 3′ guanine of PtGpG ( Supplementary Fig. 3 and Supplementary Table 1 ), analogous to the ~50% reduction in catalytic efficiency of the polymerase observed opposite the 3′ thymine of a thymine-thymine dimer 8 . The 5′ guanine of PtGpG is almost perpendicular to the 3′ guanine and is located toward the outside edge of the human Pol-η active site cleft in intimate contact with Ser62 ( Fig. 3a) . As such, the position and orientation of the 5′ guanine is different from the 5′ thymine of a thymine-thymine dimer (Fig. 2b) , which is less angularly inclined and fits directly within the active site cleft, farther away from Ser62. Because the 5′ guanine of PtGpG is toward the periphery of the active site cleft, it has no direct interactions with Arg61, analogous to those observed with the 5′ thymine of a thyminethymine dimer. That is, whereas Arg61 assumes three rotamers in the Highlighted and labeled are the catalytic residues (Asp13, Asp115 and Glu116) and the residues that interact with the triphosphate moiety of incoming nucleotide (Tyr52 and Arg55). Arg61 has one conformation in the PtGpG ternary complex where it interacts with the incoming dCTP; by contrast, Arg61 adopts multiple conformations in the cis-syn thymine-thymine dimer ternary complex.
a r t i c l e s structure with a thymine-thymine dimer 8 , one of which interacts with the 5′ thymine and the other two with the incoming dATP ( Fig. 3b) , Arg61 assumes a single conformation with PtGpG and interacts exclusively with the incoming dCTP (Fig. 3a) . This difference may underlie the milder effect of the R61A mutation for the incorporation of dCTP opposite the 3′ guanine of PtGpG ( Supplementary Fig. 3 and Supplementary Table 1 ) compared to the ~60% reduction in catalytic efficiency observed opposite the 3′ thymine of a thymine-thymine dimer 8 . We observed the most marked effect for the Q38A R61A double mutant, in which dCTP incorporation was reduced by ~90% opposite the 3′ guanine on both undamaged and PtGpG DNA ( Supplementary  Fig. 3 and Supplementary Table 1 ). Collectively, based on our structural and biochemical observations, we infer a crucial role for Gln38 and Arg61 in the bypass of the PtGpG adduct by human Pol-η.
Error-free bypass
The 3′ guanine of PtGpG makes an almost perfect Watson-Crick base pair with incoming dCTP (Fig. 3a) , with a relatively low propeller twist (~0.4°) between the bases and classical hydrogen bonds between O6, N1 and N2 of guanine, and N4, N3 and O2 of cytosine, respectively. At the same time, the triphosphate moiety of dCTP is interlaced between the fingers and palm domains and makes hydrogen bonds with Tyr52 and Arg55 from the fingers domain and Lys231 from the palm domain (Fig. 3a) . The catalytic residues Asp13, Asp115 and Glu116 are arrayed between the dCTP triphosphate and the primer terminus. Notably, there is one Mg 2+ ion at a position that is analogous to the 'metal B' present in DNA polymerases, as compared to the two Mg 2+ ions found in previous human Pol-η structures 8 (Fig. 3) . This is probably because the primer in our structure contains a dideoxy terminus, as compared to the deoxy terminus present in previous human Pol-η structures. Nevertheless, the putative 3′ hydroxide (at the primer terminus) in our structure is located ~3.1 Å from the dCTP α phosphate and is aligned with respect to the Pα-O3′ bond (at an angle of ~160°) for an in-line nucleophilic attack, leading to the incorporation of cytosine opposite the 3′ guanine of the PtGpG adduct.
DISCUSSION
Tumor resistance often arises from the use of cisplatin as a treatment during cancer 1, 3 . The ability of human Pol-η to bypass cisplatin-DNA adducts formed during cancer chemotherapy is one crucial mechanism by which tumors seem to gain such resistance 4 . We show here that human Pol-η can accommodate a bulky PtGpG DNA crosslink within its active site cleft without any major rearrangement of the enzyme. The specificity of human Pol-η for PtGpG, as compared to other DNA polymerases, derives from an active site cleft that is sufficiently open to permit not only near perfect Watson-Crick geometry of the nascent PtGpG-dCTP base pair but also to accommodate the steeply inclined 5′ guanine of PtGpG without any steric hindrance. The specificity for PtGpG is further augmented by the residues Gln38 and Ser62, which interact with the 3′ guanine and the 5′ guanine of the PtGpG adduct, respectively, and Arg61, which interacts with incoming dCTP. Among the human TLS polymerases 5 , Arg61 and Ser62 are unique to Pol-η, whereas Gln38 occurs only in Pol-η and Pol-. In the structure of yeast Pol-η, in complex with a cisplatin-DNA adduct, Gln55 and Arg73 make similar local interactions with DNA as Gln38 and Arg61 in human Pol-η do. By contrast, in the structure of the prokaryotic DNA polymerase IV (Dpo4)-PtGpG complex that lacks these amino acids, the 3′ guanine is tilted and shifted toward the major groove and is unable to make a Watson-Crick base pair with incoming dCTP 18 . Thus, interactions with Gln38 and Ser62 seem to be necessary to keep the PtGpG optimally oriented for proper Watson-Crick base pairing between the 3′ guanine and the incoming dCTP. The human Pol-η active site cleft is well poised for catalysis and the incorporation of cytosine opposite the 3′ guanine of PtGpG. Thus, even though PtGpG is a larger and more distorted intrastrand crosslink than a cis-syn thymine-thymine dimer, it does not lead to any substantial perturbation of the human Pol-η active site or affect the ability of the polymerase to carry out catalysis. The primer terminus is well aligned for the incorporation of cytosine opposite the 3′ guanine of the PtGpG adduct. By contrast, based on our biochemical studies, human Pol-η is markedly inhibited in extending from the 3′ guanine, the 5′ guanine or the next templating residue of the PtGpG adduct (Supplementary Fig. 3) . This may be one reason why we were unsuccessful in obtaining suitable crystals for a ternary complex of human Pol-η inserting a nucleotide opposite the 5′ guanine of the PtGpG adduct. A recurring theme in TLS is that lesion bypass often requires the sequential action of two polymerases: an 'inserter' and an 'extender' 5 . The inserter is efficient at inserting an incoming nucleotide across from the lesion, and the extender is recruited to add bases downstream of the lesion. In eukaryotes, Pol-ζ, a B-family polymerase, is specialized for the extension step of lesion bypass 19 , and it is conceivable that Pol-ζ (or another polymerase) is recruited in human cells to complete the PtGpG bypass.
The ability of human Pol-η to replicate across from a cisplatin adduct makes it an attractive target for cancer therapy. A pressing issue is whether one can design or identify inhibitors that are specific for human Pol-η. The fact that the shape of the human Pol-η active site cleft is different from that of other DNA polymerases suggests that it would be possible to derive small molecules that can specifically inhibit human Pol-η. The human Pol-η active site cleft, for example, is more open than it is in other DNA polymerases, and it lacks elements such as the N-clasp that is present in human Pol-κ and the N-digit that is present in human Rev1 (refs. 20,21) . Also, the presence of unique (Arg61 and Ser62) and nearly unique (Gln38) residues within the active site cleft of human Pol-η offer the possibility of specific hydrogen bonds with unique small molecules.
METhODS
Methods and any associated references are available in the online version of the paper.
ONLINE METhODS
Preparation of protein and DNA for crystallization. The catalytic core of human Pol-η (residues 1-432) harboring an N-terminal His 6 tag and a C406M mutation was overexpressed in Escherichia coli and purified as previously described 8 . Briefly, the His 6 tag was removed by overnight incubation with PreScission protease, and the protein was subsequently purified by ionexchange (MonoS) and size-exclusion (Superdex 75) chromatography before concentration of the protein for crystallization experiments. An HPLC-purified 13-nt template strand (5′-CTTGGTCTCCTCC-3′) was prepared (Integrated DNA Technologies Inc.), and a cis-diamminedichloroplatinum(II) (cisplatin; GFS Chemicals Inc.) intrastrand d(GpG) cross-link was introduced between the two adjacent guanines based on a previously described method 16 . The cisplatinmodified template strand was further purified by HPLC on a reversed-phase C18 column (Waters Inc.) A 9-nt primer strand harboring a dideoxyadenosine at its 3′ end (5′-TGGAGGAGA dd -3′) was annealed at a molar ratio of 1:1 to the 13-nt cisplatin-modified template strand to yield the primer-template (9 nt and 13 nt, respectively).
Preparation of proteins for biochemical analysis.
The full-length wild-type and various mutant versions of human Pol-η were expressed in yeast S. cerevisiae and purified by Glutathione Sepharose affinity chromatography, as described previously 22 , except that the proteins contained tandem N-terminal glutathione S-transferase (GST) and Flag tags. The GST tags were removed by treatment with PreScission protease, leaving an N-terminal Flag tag attached to each protein.
Proteins were quantified using Coomassie blue-stained SDS-PAGE analysis. Mutations were introduced into the wild-type open reading frame by PCR using oligonucleotides containing site-specific mutations and were confirmed by sequencing before expression.
DNA polymerase assays. DNA substrates consisted of a radiolabeled oligonucleotide primer annealed to a 78-nt oligonucleotide DNA template by heating a mixture of the primer-template at a 1:1.5 molar ratio to 95 °C and allowing it to cool to room temperature for several hours. The template 78-mer oligonucleotide contained the sequence 5′-AGCAAGTCAC CAATGTCTAA GAGTTTCTTGGTCTCCTCCT ACACTGGAGT ACCGGAGCAT CGTCGTGACT GGGAAAAC-3′ and was either undamaged or harbored a guanine-platinum-guanine intrastrand cross-link at the underlined position. The sequence of the running-start primer used is 5′-CGACGATGCTCCGGT ACTCCAGTGTAG-3′. For the steady-state kinetic analyses of the nucleotide insertion opposite the 3′ guanine of either the undamaged guanine-guanine or the guanine-guanine cisplatin template, the primer 5′-GATGCTCCGG TACTCCAGTG TAGGAGGAGA-3′ was used. The standard DNA polymerase reaction (5 µl) contained 25 mM Tris-HCl (pH 7.5), 5 mM MgCl 2, 1 mM dithiothreitol, 100 µg ml −1 BSA, 10% glycerol and 10 nM DNA substrate. For the running-start assays, 25 µM each of dATP, deoxythymidine triphosphate (dTTP), dCTP and deoxyguanosine triphosphate (dGTP) (Roche Biochemicals) was included. For the steady-state kinetic experiments, only dCTP was included at concentrations ranging from 0.05 µM to 50 µM. Reactions containing wildtype and mutant Pol-η (0.05-0.5 nM) were carried out at 37 °C for 5-10 min. Reactions were terminated by the addition of six volumes of loading buffer (95% formamide, 0.05% cyanol blue and 0.05% bromophenol blue) before being resolved on 12% polyacrylamide gels containing 8 M urea. Gels were dried before autoradiography.
Steady-state kinetic analysis. Steady-state kinetic analyses for the deoxynucleotide incorporation were carried out as described 22 . Gel band intensities of the substrate and the products of the deoxynucleotide incorporation reactions were quantified using a PhosphorImager and the ImageQuant software (Molecular Dynamics). The observed rate of deoxynucleotide incorporation, v obs , was determined by dividing the amount of product formed by the reaction time and protein concentration. The v obs was graphed as a function of the deoxynucleotide concentration, and the data were fit to the Michaelis-Menten equation describing a hyperbola: v obs = (k cat [E] × [dNTP])/(K m + [dNTP]). From the best-fit curve, the apparent K m and k cat steady-state kinetics parameters were obtained for the incorporation of dCTP by the wild-type and mutant Pol-η, and the efficiencies of the nucleotide incorporation (k cat /K m ) were determined.
Cocrystallization. The cisplatin (PtGpG) ternary complex was prepared by mixing human Pol-η with the cisplatin-modified primer-template in a 1:1.1 molar ratio in the presence of 2 mM dCTP and 5 mM MgCl 2 . This mix was incubated for at least 1 h before crystallization. Thin, needle-like crystals were obtained in 0.1 M Bis-Tris (pH 5.5) and 30-35% (w/v) PEG 1500 by the vapor diffusion method at 20 °C. Several rounds of microseeding (15-30% PEG 1500) were required to produce good-quality crystals. For data collection, the crystals were cryoprotected by stepwise soaks for 5 min in mother liquor solutions containing 5-30% (v/v) glycerol and were then flash frozen in liquid nitrogen. X-ray diffraction data were collected on beamline X25 at Brookhaven National Laboratory. The crystals diffracted to a 2.32-Å resolution with synchrotron radiation at the platinum L III absorption edge (λ = 1.0722 Å). The crystals belonged to the space group P6(1) with unit cell dimensions a = 98.5 Å, b = 98.5 Å and c = 82.6 Å. A Matthew's coefficient calculation indicated one protein-DNA complex in the asymmetric unit.
Structure determination and refinement. The structure was solved by molecular replacement using the human Pol-η ternary structure (PDB 3MR2), with the DNA, incoming nucleotide, metals and water molecules omitted, as the starting model 8 . The program PHASER gave a unique molecular replacement solution 23 . The first round of refinement and map calculation was carried out with just the enzyme using Refmac 24 . The electron density maps (2F o -F c and F o -F c ) showed unambiguous densities for the cisplatin 1, 2 intrastrand cross-link between the adjacent guanines in the template strand ( Fig. 1d,e) , the primer strand, the incoming nucleotide and the metal, which were then iteratively built into the map using Coot 25 . Iterative rounds of refinement and water picking were carried out using Refmac, and the model building was carried out using Coot. The final model had excellent stereochemistry ( Fig. 1) , as shown by MolProbity, with 97.9% of the residues being located in the most favored regions of the Ramachandran plot 17 . Figures were prepared using PyMol (http://www.pymol.org/).
